PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32321460-0 2020 Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib. Sunitinib 91-100 adhesion G protein-coupled receptor L4 Homo sapiens 18-23 32321460-9 2020 RESULTS: Patients with high ELTD1 expression in the tumor vasculature experienced a significantly better progression free survival (PFS) with sunitinib treatment as compared to patients with low ELTD1 expression (8 versus 5.5 months, respectively). Sunitinib 142-151 adhesion G protein-coupled receptor L4 Homo sapiens 28-33 32321460-12 2020 CONCLUSIONS: Our results identify tumor vessel ELTD1 expression as a positive predictive marker for sunitinib-treatment in patients suffering from mRCC. Sunitinib 100-109 adhesion G protein-coupled receptor L4 Homo sapiens 47-52